

4 October 2023

ASX Announcement

Notice of Meeting - Correction

The Notice of Meeting announced on Monday 2 October 2023 referred to Non-Executive Director Christine Emmanuel-Donnelly as a patent and trademarks attorney which is not accurate due to pending registration renewal.

Ms. Emmanuel-Donnelly was also appointed as a Non-Executive Director of ImpediMed (ASX:IPD) on 28 September 2023.

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

Further information:

Jan Gielen
CFO & Company Secretary
Mobile: + 61 411 787 123

About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM, NovoSorb MTX) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information see polynovo.com

About NovoSorb®

NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through surgery, trauma or burn. NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

Reach

PolyNovo supplies approximately 638 hospitals directly in Australia, Hong Kong, India, Ireland, the Middle East, New Zealand, Singapore, the United Kingdom, and the United States. Other countries, such as Canada, Germany, France and Spain are serviced by a distributor.